Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes
Baldassarre MPA, Di Dalmazi G, Carrieri F, et al. (2026). Diabetes, Obesity and Metabolism.
Summary
A retrospective study of 232 adults with type 2 diabetes who started oral semaglutide at one Italian diabetes clinic, followed for 24 months. Over that time HbA1c fell by 0.8 percentage points and body weight by 5.7 kg on average; total and LDL cholesterol also fell, and kidney measures (eGFR and urine albumin) stayed stable. 44% reached a combined target of HbA1c at or below 7% with at least 5% weight loss by 24 months, and 68.5% were still on the drug at 24 months. Among those who stopped, switching to another GLP-1 receptor agonist was the most common next step. No new safety concerns were reported. As a single-centre study without a comparison group, it describes outcomes in routine care rather than testing the drug against an alternative.